Adertis Healthmark Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 9 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.12 M
- Revenue Growth -45.68%
- Profit Growth -61.00%
- Ebitda 6.27%
- Net Worth 6.61%
- Total Assets 11.68%
About Adertis Healthmark
Adertis Healthmark Private Limited (AHPL) is a Private Limited Indian Non-Government Company incorporated in India on 15 September 2015 (Nine years and five months 11 days old ). Its registered office is in Ambala, Haryana, India.
The Corporate was formerly known as Abertis Healthmark Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.12 M.
Birbal Sharma and Sikandar Shaw serve as directors at the Company.
Company Details
- Location
Ambala, Haryana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51909HR2015PTC056650
- Company No.
056650
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Sep 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Adertis Healthmark?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Birbal Sharma  | Director | 15-Sep-2015 | Current |
| Sikandar Shaw | Additional Director | 07-Mar-2024 | Current |
Financial Performance of Adertis Healthmark.
Adertis Healthmark Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 45.68% decrease. The company also saw a substantial fall in profitability, with a 61% decrease in profit. The company's net worth moved up by a moderate rise of 6.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Adertis Healthmark?
In 2021, Adertis Healthmark had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.12 M
₹0
Charges Breakdown by Lending Institutions
- Central Bank Of India : 0.11 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 08 Jun 2020 | Central Bank Of India | ₹0.17 M | Open |
| 30 Dec 2019 | Central Bank Of India | ₹0.95 M | Open |
How Many Employees Work at Adertis Healthmark?
Unlock and access historical data on people associated with Adertis Healthmark, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Adertis Healthmark, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Adertis Healthmark's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
